AABB Committee Report: Reducing transfusion-transmitted cytomegalovirus infections

Transfusion

Volumn 56, Issue 6, 2016, Pages 1581-1587

  Heddle, Nancy M ^a,b   Boeckh, Michael ^c   Grossman, Brenda ^d   Jacobson, Jessica ^e   Kleinman, Steven ^f,j   Tobian, Aaron A R ^g   Webert, Kathryn ^b   Wong, Edward C C ^h   Roback, John D ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e BELLEVUE HOSPITAL CENTER   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j AABB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD COMPONENT; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; COMPARATIVE EFFECTIVENESS; CYTOMEGALOVIRUS INFECTION; ENZYME IMMUNOASSAY; ERYTHROCYTE TRANSFUSION; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; PATIENT CARE; PATIENT PREFERENCE; PLASMA TRANSFUSION; PRACTICE GUIDELINE; THROMBOCYTE TRANSFUSION; TRANSFUSION MEDICINE; TRANSFUSION TRANSMITTED CYTOMEGALOVIRUS INFECTION; BLOOD; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; FEMALE; IMMUNOLOGY; LEUKAPHERESIS; MALE; PREGNANCY; PROCEDURES; SEROLOGY; STANDARDS; TRANSMISSION;

VIRUS ANTIBODY;

ANTIBODIES, VIRAL; BLOOD TRANSFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MALE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; SEROLOGIC TESTS; TRANSFUSION REACTION;

EID: 84960510261     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13503     Document Type: Article

References (42)

1. Ho M., Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12 Suppl 7: S701-10.
2. Roback JD, Josephson CD., New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell-associated viral infections. Transfusion 2013; 53: 2112-6.
3. Slobedman B, Mocarski ES., Quantitative analysis of latent human cytomegalovirus. J Virol 1999; 73: 4806-12.
4. Wu, Y, Zou, Cable, S, Dorsey, R, et al., Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2010; 50: 776-86.
5. Dumont LJ, Luka J, VandenBroeke T, et al., The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods. Blood 2001; 97: 3640-7.
6. National Academies of Sciences, Engineering, and Medicine; Institute of Medicine. Clinical practice guidelines we can trust. 2011. Washington, DC: National Academies Press.
7. Wiegmann TL, Mintz PD., The growing role of AABB clinical practice guidelines in improving patient care. Transfusion 2015; 55: 935-6.
8. Guyatt GH, Oxman AD, Vist GE, et al., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
9. Terracciano L, Brozek J, Compalati E, et al., GRADE system: new paradigm. Curr Opin Allergy Clin Immunol 2010; 10: 377-83.
10. Guyatt GH, Oxman AD, Kunz R, et al., GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395-400.
11. Roback JD, Caldwell S, Carson J, et al., Evidence-based practice guidelines for plasma transfusion. Transfusion 2010; 50: 1227-39.
12. Carson JL, Grossman BJ, Kleinman S, et al., Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2012; 157: 49-58.
13. Kaufman RM, Djulbegovic B, Gernsheimer T, et al., Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162: 205-13.
14. Mainou M, Alahdab F, Tobian A, et al., Reducing the risk of transfusion transmitted cytomegalovirus (CMV) infection: a systematic review and meta-analysis. Transfusion. In press 2016.
15. Xu D, Yonetani M, Uetani Y, et al., Acquired cytomegalovirus infection and blood transfusion in preterm infants. Acta Paediatr Jpn 1995; 37: 444-9.
16. Eisenfeld L, Silver H, McLaughlin J, et al., Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32: 205-9.
17. Bowden RA, Slichter SJ, Sayers MH, et al., Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-50.
18. Gilbert GL, Hayes K, Hudson IL, et al., Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal cytomegalovirus infection study group [see comments]. Lancet 1989; 1: 1228-31.
19. Murphy MF, Grint PC, Hardiman AE, et al., Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia [letter]. Br J Haematol 1988; 70: 253-4.
20. Ohto H, Ujie N, Hirai K., Lack of difference in cytomegalovirus transmission via the transfusion of filtered-irradiated and nonfiltered-irradiated blood to newborn infants in an endemic area. Transfusion 1999; 39: 201-5.
21. Nichols WG, Price TH, Gooley T, et al., Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-200.
22. Bowden RA, Slichter SJ, Sayers M, et al., A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
23. Kekre N, Tokessy M, Mallick R, et al., Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 2013; 19: 1719-24.
24. Ljungman P, Larsson K, Kumlien G, et al., Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 2002; 34: 347-50.
25. Pamphilon D, Foot A, Adeodu A, et al., Prophylaxis and prevention of CMV infection in BM allograft recipients: leukodepleted platelets are equivalent to those form CMV-seronegative donors. Bone Marrow Transplant 1999; S66: 213.
26. Yeager AS, Palumbo PE, Malachowski N, et al., Sequelae of maternally derived cytomegalovirus infections in premature infants. J Pediatr 1983; 102: 918-22.
27. Simanek AM, Dowd JB, Pawelec G, et al., Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 2011; 6: e16103.
28. th international workshop on CMV and Immunosenescence-a shadow of cytomegalovirus infection on immunological memory. Eur J Immunol 2015; 45: 954-7.
29. Barnes LL, Capuano AW, Aiello AE, et al., Cytomegalovirus infection and risk of alzheimer disease in older black and white individuals. J Infect Dis 2015; 211: 230-7.
30. Smith D, Lu Q, Yuan S, et al., Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the united states: leucoreduction vs. cytomegalovirus-seronegative. Vox Sang 2010; 98: 29-36.
31. Lieberman L, Devine DV, Reesink HW, et al., Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: standards of care. Vox Sang 2014; 107: 276-311.
32. Josephson CD, Caliendo AM, Easley KA, et al., Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr 2014; 168: 1054-62.
33. Nash T, Hoffmann S, Butch S, et al., Safety of leukoreduced, cytomegalovirus (CMV)-untested components in CMV-negative allogeneic human progenitor cell transplant recipients. Transfusion 2012; 52: 2270-2.
34. Thiele T, Kruger W, Zimmermann K, et al., Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51: 2620-6.
35. Hall S, Danby R, Osman H, et al., Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience. Transfus Med 2015 Jun 26. doi: 10.1111/tme.12219. [Epub ahead of print].
36. Ziemann M, Heuft HG, Frank K, et al., Window period donations during primary cytomegalovirus infection and risk of transfusion-transmitted infections. Transfusion 2013; 53: 1088-94.
37. Ziemann M, Juhl D, Gorg S, et al., The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013; 53: 2183-9.
38. Jordan CT, Saakadze N, Newman JL, et al., Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet a light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004; 44: 1159-65.
39. Keil SD, Saakadze N, Bowen R, et al., Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products. Transfusion 2015; 55: 858-63.
40. Seed CR, Wong J, Polizzotto MN, et al., The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components. Vox Sang 2015; 109: 11-7.
41. MacPherson H., Pragmatic clinical trials. Complement Ther Med 2004; 12: 136-40.
42. Luce BR, Kramer JM, Goodman SN, et al., Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009; 151: 206-9.